Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein

< 0.1 EU/μg of the protein by LAL method.

ice pack

15.13 kDa

Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Ile 56 - Glu 182) of human DR5 (Accession #NP_003833.3) fused with a 6×His tag at the C-terminus.

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

C-His

Bio-Markers & CD Antigens, TNF family, Biosimilar Drug Targets

1. Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human TRAIL at 2 μg/mL (100 μL/well) can bind Recombinant Human DR5 with a linear range of 14-56 ng/mL.|2. Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED₅₀ for this effect is 0. 38-1. 5 pg/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10. |3. Measured by its binding ability in a functional ELISA.Immobilized Human TRAIL / TNFSF10 Protein at 2μg/mL (100 μL/well) can bind Human CD262 Protein with a linear range of 0. 5-14. 1 ng/mL.

15.13 kDa